5 research outputs found
Comparison of different technologies for producing recombinant adeno-associated virus on a laboratory scale
Adeno-associated virus vectors are among the most promising ones for the delivery of transgenes to various organs and tissues. Recombinant adeno-associated virus (rAAV) is able to transduce both dividing and non-dividing cells, has low immunogenicity, and is able to provide long-term expression of transgenes. Modern technologies make it possible to obtain rAAV for in vivo use, but they are not without drawbacks associated with laboriousness, scalability difficulties, and high cost, therefore, improvement of technological schemes for obtaining rAAV is an urgent issue. The aim of the study was to compare different technological approaches to rAAV production based on different conditions of the transfected HEK293 cell line cultivation on a laboratory scale. Materials and methods: HEK293 cell culture, AAV-DJ Packaging System, PlasmidSelect Xtra Starter Kit were used in the study. The technologies were compared using a model rAAV vector with a single-domain antibody transgene fused to the Fc-fragment of IgG1 specific to botulinum toxin. HEK293 cells were transfected with supercoiled plasmid DNA isolated by three-step chromatographic purification. The identity of the rAAV preparation was determined by electrophoresis, immunoblotting, and real-time polymerase chain reaction. Results: the study demonstrated the efficiency of the chromatographic method for obtaining a supercoiled form of plasmid DNA that can be used for efficient transfection of cell culture in order to produce rAAV. The study compared the following processes of rAAV production: using transient transfection and cultivation of the transfected HEK293 cell suspension in Erlenmeyer flasks, adherent culture in T-flasks, and adherent culture in a BioBLU 5p bioreactor on a matrix of Fibra-Cel disks. Conclusions: the data obtained showed the possibility of using the described approaches to purification of plasmid DNA, cell transfection, and cultivation of the transfected cells under various conditions to obtain rAAV samples that expresses the antibody gene. The BioBLU 5p reactor with Fibra-Cel discs was used for the first time to produce preparative quantities of rAAV on a laboratory scale, which increased the adherent surface area during cell culture and transfection, and, as a result, increased the yield of the target product
Π‘ΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΠ΅Ρ Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΠ΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΠΎΠ³ΠΎ Π°Π΄Π΅Π½ΠΎΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠ° Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΌΠ°ΡΡΡΠ°Π±Π΅
Adeno-associated virus vectors are among the most promising ones for the delivery of transgenes to various organs and tissues. Recombinant adeno-associated virus (rAAV) is able to transduce both dividing and non-dividing cells, has low immunogenicity, and is able to provide long-term expression of transgenes. Modern technologies make it possible to obtain rAAV for in vivo use, but they are not without drawbacks associated with laboriousness, scalability difficulties, and high cost, therefore, improvement of technological schemes for obtaining rAAV is an urgent issue. The aim of the study was to compare different technological approaches to rAAV production based on different conditions of the transfected HEK293 cell line cultivation on a laboratory scale. Materials and methods: HEK293 cell culture, AAV-DJ Packaging System, PlasmidSelect Xtra Starter Kit were used in the study. The technologies were compared using a model rAAV vector with a single-domain antibody transgene fused to the Fc-fragment of IgG1 specific to botulinum toxin. HEK293 cells were transfected with supercoiled plasmid DNA isolated by three-step chromatographic purification. The identity of the rAAV preparation was determined by electrophoresis, immunoblotting, and real-time polymerase chain reaction. Results: the study demonstrated the efficiency of the chromatographic method for obtaining a supercoiled form of plasmid DNA that can be used for efficient transfection of cell culture in order to produce rAAV. The study compared the following processes of rAAV production: using transient transfection and cultivation of the transfected HEK293 cell suspension in Erlenmeyer flasks, adherent culture in T-flasks, and adherent culture in a BioBLU 5p bioreactor on a matrix of Fibra-Cel disks. Conclusions: the data obtained showed the possibility of using the described approaches to purification of plasmid DNA, cell transfection, and cultivation of the transfected cells under various conditions to obtain rAAV samples that expresses the antibody gene. The BioBLU 5p reactor with Fibra-Cel discs was used for the first time to produce preparative quantities of rAAV on a laboratory scale, which increased the adherent surface area during cell culture and transfection, and, as a result, increased the yield of the target product.ΠΠ΅ΠΊΡΠΎΡΡ Π½Π° ΠΎΡΠ½ΠΎΠ²Π΅ Π°Π΄Π΅Π½ΠΎΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π²ΠΈΡΡΡΠ° ΡΠ²Π»ΡΡΡΡΡ ΠΎΠ΄Π½ΠΈΠΌΠΈ ΠΈΠ· Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
Π΄Π»Ρ Π΄ΠΎΡΡΠ°Π²ΠΊΠΈ ΡΡΠ°Π½ΡΠ³Π΅Π½ΠΎΠ² Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΠ΅ ΠΎΡΠ³Π°Π½Ρ ΠΈ ΡΠΊΠ°Π½ΠΈ. Π Π΅ΠΊΠΎΠΌΠ±ΠΈΠ½Π°Π½ΡΠ½ΡΠΉ Π°Π΄Π΅Π½ΠΎΠ°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΉ Π²ΠΈΡΡΡ (rAAV) ΡΠΏΠΎΡΠΎΠ±Π΅Π½ ΡΡΠ°Π½ΡΠ΄ΡΡΠΈΡΠΎΠ²Π°ΡΡ ΠΊΠ°ΠΊ Π΄Π΅Π»ΡΡΠΈΠ΅ΡΡ, ΡΠ°ΠΊ ΠΈ Π½Π΅Π΄Π΅Π»ΡΡΠΈΠ΅ΡΡ ΠΊΠ»Π΅ΡΠΊΠΈ, ΠΎΠ±Π»Π°Π΄Π°Π΅Ρ Π½ΠΈΠ·ΠΊΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΡΡ ΠΈ ΡΠΏΠΎΡΠΎΠ±Π΅Π½ ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡ Π΄ΠΎΠ»Π³ΠΎΡΡΠΎΡΠ½ΡΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ ΡΡΠ°Π½ΡΠ³Π΅Π½ΠΎΠ². ΠΠ° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΡΡΡΠ΅ΡΡΠ²ΡΡΡ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡΠΈΠ΅ ΠΏΠΎΠ»ΡΡΠ°ΡΡ rAAV Π΄Π»Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ in vivo, ΠΎΠ΄Π½Π°ΠΊΠΎ ΠΎΠ½ΠΈ Π½Π΅ Π»ΠΈΡΠ΅Π½Ρ Π½Π΅Π΄ΠΎΡΡΠ°ΡΠΊΠΎΠ², ΡΠ²ΡΠ·Π°Π½Π½ΡΡ
Ρ ΡΡΡΠ΄ΠΎΠ΅ΠΌΠΊΠΎΡΡΡΡ, ΡΠ»ΠΎΠΆΠ½ΠΎΡΡΡΠΌΠΈ ΠΌΠ°ΡΡΡΠ°Π±ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΈ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠΎΠΈΠΌΠΎΡΡΡΡ, ΠΏΠΎΡΡΠΎΠΌΡ Π²ΠΎΠΏΡΠΎΡ ΠΎΠ± ΡΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΡ
Π΅ΠΌ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ rAAV ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΡΠΌ.Β Π¦Π΅Π»Ρ ΡΠ°Π±ΠΎΡΡ: ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ rAAV, ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΡΡ
Π½Π° ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π½ΡΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π»ΠΈΠ½ΠΈΠΈ HEK293 Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΌΠ°ΡΡΡΠ°Π±Π΅.Β ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ: Π² ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ ΠΊΡΠ»ΡΡΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ HEK293, ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΡΡ ΡΠΈΡΡΠ΅ΠΌΡ AAV-DJ Packaging System, ΡΠΈΡΡΠ΅ΠΌΡ PlasmidSelect Xtra Starter Kit. Π ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ ΠΌΠΎΠ΄Π΅Π»ΠΈ Π΄Π»Ρ ΡΡΠ°Π²Π½Π΅Π½ΠΈΡ ΡΠ΅Ρ
Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π»ΠΈ Π²Π΅ΠΊΡΠΎΡ rAAV Ρ ΡΡΠ°Π½ΡΠ³Π΅Π½ΠΎΠΌ ΠΎΠ΄Π½ΠΎΠ΄ΠΎΠΌΠ΅Π½Π½ΠΎΠ³ΠΎ Π°Π½ΡΠΈΡΠ΅Π»Π°, ΡΠ»ΠΈΡΠΎΠ³ΠΎ Ρ Fc-ΡΡΠ°Π³ΠΌΠ΅Π½ΡΠΎΠΌ IgG1, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΠ³ΠΎ ΠΊ Π±ΠΎΡΡΠ»ΠΎΡΠΎΠΊΡΠΈΠ½Ρ. ΠΡΠΈΠΌΠ΅Π½ΡΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄ ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ HEK293 ΡΡΠΏΠ΅ΡΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠΉ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ, Π²ΡΠ΄Π΅Π»Π΅Π½Π½ΠΎΠΉ ΠΏΡΠΈ ΠΏΠΎΠΌΠΎΡΠΈ ΡΡΠ΅Ρ
ΡΡΡΠΏΠ΅Π½ΡΠ°ΡΠΎΠΉ Ρ
ΡΠΎΠΌΠ°ΡΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΠΈΡΡΠΊΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠΎΠ΄Π»ΠΈΠ½Π½ΠΎΡΡΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° rAAV ΠΏΡΠΎΠ²ΠΎΠ΄ΠΈΠ»ΠΈ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌΠΈ ΡΠ»Π΅ΠΊΡΡΠΎΡΠΎΡΠ΅Π·Π°, ΠΈΠΌΠΌΡΠ½ΠΎΠ±Π»ΠΎΡΡΠΈΠ½Π³Π° ΠΈ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅ΠΆΠΈΠΌΠ΅ ΡΠ΅Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ.Β Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ: ΠΏΡΠΎΠ΄Π΅ΠΌΠΎΠ½ΡΡΡΠΈΡΠΎΠ²Π°Π½Π° ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΡΡΠΏΠ΅ΡΡΠΊΡΡΡΠ΅Π½Π½ΠΎΠΉ ΡΠΎΡΠΌΡ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ, ΠΏΡΠΈΠΌΠ΅Π½ΠΈΠΌΠΎΠΉ Π΄Π»Ρ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ Ρ ΡΠ΅Π»ΡΡ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ rAAV. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΡΡΠ°Π²Π½Π΅Π½ΠΈΠ΅ ΠΏΡΠΎΡΠ΅ΡΡΠ° ΡΡΠ°Π½Π·ΠΈΠ΅Π½ΡΠ½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π½ΡΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ HEK293 Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ
ΡΡΡΠΏΠ΅Π½Π·ΠΈΠΈ Π² ΠΊΠΎΠ»Π±Π°Ρ
, Π°Π΄Π³Π΅Π·ΠΈΠΈ Π² ΠΊΡΠ»ΡΡΡΡΠ°Π»ΡΠ½ΡΡ
ΡΠ»Π°ΠΊΠΎΠ½Π°Ρ
ΠΈ Π°Π΄Π³Π΅Π·ΠΈΠΈ Π² Π±ΠΈΠΎΡΠ΅Π°ΠΊΡΠΎΡΠ΅ BioBLU 5p Π½Π° ΠΌΠ°ΡΡΠΈΡΠ΅ ΠΈΠ· Π΄ΠΈΡΠΊΠΎΠ² Fibra-Cel Ρ ΡΠ΅Π»ΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΠΈΠΈ rAAV.Β ΠΡΠ²ΠΎΠ΄Ρ: ΠΏΠΎΠΊΠ°Π·Π°Π½Π° Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΠΏΠΈΡΠ°Π½Π½ΡΡ
ΠΏΠΎΠ΄Ρ
ΠΎΠ΄ΠΎΠ² ΠΊ ΠΎΡΠΈΡΡΠΊΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ, ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ ΠΈ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠ°Π½ΡΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΊΠ»Π΅ΡΠΎΠΊ Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ
ΡΡΠ»ΠΎΠ²ΠΈΡΡ
Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ° rAAV, ΡΡΠΏΡΠ΅ΡΡΠΈΡΡΡΡΠ΅Π³ΠΎ Π³Π΅Π½ Π°Π½ΡΠΈΡΠ΅Π»Π°. Π Π΅Π°ΠΊΡΠΎΡ BioBLU 5p Ρ Π΄ΠΈΡΠΊΠ°ΠΌΠΈ Fibra-Cel Π±ΡΠ» Π²ΠΏΠ΅ΡΠ²ΡΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ Π΄Π»Ρ ΠΏΠΎΠ»ΡΡΠ΅Π½ΠΈΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈΠ²Π½ΡΡ
ΠΊΠΎΠ»ΠΈΡΠ΅ΡΡΠ² rAAV Π² Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠ½ΠΎΠΌ ΠΌΠ°ΡΡΡΠ°Π±Π΅, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ»ΠΎ ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΠΏΠ»ΠΎΡΠ°Π΄Ρ ΠΏΠΎΠ²Π΅ΡΡ
Π½ΠΎΡΡΠΈ Π°Π΄Π³Π΅Π·ΠΈΠΈ ΠΏΡΠΈ ΠΊΡΠ»ΡΡΠΈΠ²ΠΈΡΠΎΠ²Π°Π½ΠΈΠΈ ΠΈ ΡΡΠ°Π½ΡΡΠ΅ΠΊΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ, ΠΊΠ°ΠΊ ΡΠ»Π΅Π΄ΡΡΠ²ΠΈΠ΅, ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ Π²ΡΡ
ΠΎΠ΄ ΡΠ΅Π»Π΅Π²ΠΎΠ³ΠΎ ΠΏΡΠΎΠ΄ΡΠΊΡΠ°
rAAV expressing recombinant antibody for emergency prevention and long-term prophylaxis of COVID-19
IntroductionNumerous agents for prophylaxis of SARS-CoV-2-induced diseases are currently registered for the clinical use. Formation of the immunity happens within several weeks following vaccine administration which is their key disadvantage. In contrast, drugs based on monoclonal antibodies, enable rapid passive immunization and therefore can be used for emergency pre- and post-exposure prophylaxis of COVID-19. However rapid elimination of antibody-based drugs from the circulation limits their usage for prolonged pre-exposure prophylaxis.MethodsIn current work we developed a recombinant adeno-associated viral vector (rAAV), expressing a SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibody P2C5 fused with a human IgG1 Fc fragment (P2C5-Fc) using methods of molecular biotechnology and bioprocessing.Results and discussionsA P2C5-Fc antibody expressed by a proposed rAAV (rAAV-P2C5-Fc) was shown to circulate within more than 300 days in blood of transduced mice and protect animals from lethal SARS-CoV-2 virus (B.1.1.1 and Omicron BA.5 variants) lethal dose of 105 TCID50. In addition, rAAV-P2C5-Fc demonstrated 100% protective activity as emergency prevention and long-term prophylaxis, respectively. It was also demonstrated that high titers of neutralizing antibodies to the SARS-CoV-2 virus were detected in the blood serum of animals that received rAAV-P2C5-Fc for more than 10 months from the moment of administration.Our data therefore indicate applicability of an rAAV for passive immunization and induction of a rapid long-term protection against various SARS-CoV-2 variants